Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1
暂无分享,去创建一个
E. Fisher | A. Neimann | N. Mehta | J. Berger | J. Scher | Tessa J. Barrett | J. Krueger | M. Garshick | Michael Tawil | Angela H. Lee | S. Jelic | Charissa Salud-Gnilo | M. Eppler
[1] P. Dagur,et al. Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. , 2020, The Journal of investigative dermatology.
[2] A. Khera,et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. , 2019, Circulation.
[3] W. Koenig,et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. , 2019, The Journal of investigative dermatology.
[4] E. Fisher,et al. Inflammasome Signaling and Impaired Vascular Health in Psoriasis , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[5] B. Strober,et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. , 2019, Journal of the American Academy of Dermatology.
[6] Kairong Cui,et al. Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis , 2019, JACC. Basic to translational science.
[7] A. Roddick,et al. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.
[8] J. Hochman,et al. Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. , 2019, Atherosclerosis.
[9] A. Armstrong,et al. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial , 2018, Circulation. Cardiovascular imaging.
[10] A. Assinger,et al. Measuring and interpreting platelet-leukocyte aggregates , 2018, Platelets.
[11] A. Heguy,et al. Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity , 2018, JACC. Basic to translational science.
[12] J. Freedman,et al. Circulating Platelets as Mediators of Immunity, Inflammation, and Thrombosis , 2018, Circulation research.
[13] K. Uryu,et al. Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease. , 2018, Journal of the American College of Cardiology.
[14] James A. Underberg,et al. The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis , 2017, Current Atherosclerosis Reports.
[15] H. Valdez,et al. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. , 2017, The Journal of investigative dermatology.
[16] E. Fisher,et al. Hyperglycemia enhances arsenic-induced platelet and megakaryocyte activation , 2017, Journal of Translational Medicine.
[17] J. Berger,et al. Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1&bgr; Pathway in Systemic Lupus Erythematosus , 2017, Arteriosclerosis, thrombosis, and vascular biology.
[18] Kirsten Bibbins-Domingo,et al. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.
[19] K. Ghoreschi. Faculty Opinions recommendation of Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. , 2016 .
[20] R. Wahab,et al. Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea , 2016, Science Translational Medicine.
[21] I. Bechmann,et al. Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-Like Skin Disease , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[22] Lesley M. Chapman,et al. Emerging roles for platelets as immune and inflammatory cells. , 2014, Blood.
[23] Mayte Suárez-Fariñas,et al. Immunology of psoriasis. , 2014, Annual review of immunology.
[24] G. Jemec,et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. , 2013, Journal of the American Academy of Dermatology.
[25] J. Berger,et al. Aspirin Attenuates Platelet Activation and Immune Activation in HIV-1-Infected Subjects on Antiretroviral Therapy: A Pilot Study , 2013, Journal of acquired immune deficiency syndromes.
[26] D. Dikshit,et al. Platelets and atherothrombosis: causes, targets and treatments for thrombosis. , 2013, Current medicinal chemistry.
[27] S. Devaraj,et al. Inflammation, Atherosclerosis, and Psoriasis , 2013, Clinical Reviews in Allergy & Immunology.
[28] A. Schuster,et al. Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases. , 2012, Current vascular pharmacology.
[29] Shaun P Jackson,et al. The role of platelets in atherothrombosis. , 2011, Hematology. American Society of Hematology. Education Program.
[30] P. Hundelshausen,et al. Platelets in atherosclerosis , 2011, Thrombosis and Haemostasis.
[31] Russ B Altman,et al. Platelet aggregation pathway. , 2011, Pharmacogenetics and genomics.
[32] J. Berger,et al. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data , 2011, Journal of Thrombosis and Thrombolysis.
[33] V. Fuster,et al. Aspirin: A Historical and Contemporary Therapeutic Overview , 2011, Circulation.
[34] L. Truedsson,et al. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. , 2010, Blood.
[35] Luis Puig,et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. , 2010, The Journal of investigative dermatology.
[36] R. Tamagawa‐Mineoka,et al. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. , 2010, Journal of the American Academy of Dermatology.
[37] E. Smyth. Thromboxane and the thromboxane receptor in cardiovascular disease , 2010, Clinical lipidology.
[38] E. Grove,et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease , 2010, Thrombosis and Haemostasis.
[39] P. Factor,et al. Vascular Inflammation in Obesity and Sleep Apnea , 2010, Circulation.
[40] G. Rousseau,et al. Existence of a microRNA pathway in anucleate platelets , 2009, Nature Structural &Molecular Biology.
[41] M. Abdallah,et al. Serum interferon-gamma is a psoriasis severity and prognostic marker. , 2009, Cutis.
[42] D. Gilroy,et al. Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans1 , 2009, The Journal of Immunology.
[43] Frank O. Nestle,et al. Mechanisms of Disease: Psoriasis. , 2009 .
[44] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[45] L. Jennings. Role of platelets in atherothrombosis. , 2009, The American journal of cardiology.
[46] J. Carucci,et al. Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.
[47] Yihong Yao,et al. Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.
[48] F. Nestle,et al. Immunopathogenesis of Psoriasis , 2007, Clinical reviews in allergy & immunology.
[49] G. Borthwick,et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox‐ independent mechanism , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[50] S. Daniels,et al. Recommendations for blood pressure measurement in human and experimental animals; part 1: blood pressure measurement in humans. , 2006, Hypertension.
[51] O. Boyman,et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.
[52] C. Weber. Platelets and chemokines in atherosclerosis: partners in crime. , 2005, Circulation research.
[53] G. Weissmann,et al. Modes of action of aspirin-like drugs: salicylates inhibit erk activation and integrin-dependent neutrophil adhesion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. de Waal Malefyt,et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. , 1998, The Journal of investigative dermatology.
[55] Mark Lebwohl,et al. Psoriasis , 1906, The Lancet.
[56] Daniel W. Jones,et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.
[57] K. Ley,et al. Role of platelets in the development of atherosclerosis. , 2004, Trends in cardiovascular medicine.